Intervention

degarelix

ClinicalTrials.gov intervention label

Clinical trials13

Recruiting0

Common conditions11

Lead sponsors shown7

Clinical trials

13 shown

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 2023-02-13

Safety and Efficacy of Firmagon® (Degarelix) for InjectionNCT02886598 · 2016-09-01

A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate CancerNCT02526784 · 2015-12-01

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerNCT02278185 · 2015-11-11

Pharmacokinetics of Degarelix in Chinese Patients With Prostate CancerNCT02468284 · 2015-07-01

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate CancerNCT01990196 · 2014-09-23

ACTIVE_NOT_RECRUITING

Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate CancerNCT02229253 · 2014-09-01

TRial on the Endocrine Activity of Neoadjuvant DegarelixNCT02005887 · 2014-02-01

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate CancerNCT01964170 · 2013-08-13

Firmagon (Degarelix) Intermittent TherapyNCT01512472 · 2012-01-01

Study to Find Maintenance Dose for Periodic Administration of ASP3550NCT01261572 · 2010-10-12

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate CancerNCT00738673 · 2008-07-01

Dose Finding Trial With a New Treatment (Degarelix) for Prostate CancerNCT00819156 · 2004-02-01

Common conditions

Prostate Cancer7 Adenocarcinoma of the Prostate1 Advanced Hormone Sensitive Prostate Cancer1 Breast Cancer Invasive Nos1 Metastatic Castration Resistant Prostate Cancer (mCRPC)1 Metastatic Castration Sensitive Prostate Cancer (mCSPC)1 Prostate Cancer Recurrent1 Prostatic Neoplasms1 Recurrent Prostate Cancer1 Stage III Prostate Cancer1 Stage IV Prostate Cancer1

Leading sponsors

Ferring Pharmaceuticals6 Astellas Pharma Inc2 Canadian Urology Research Consortium1 ETOP IBCSG Partners Foundation1 Jonsson Comprehensive Cancer Center1 Pfizer1 University of Colorado, Denver1

Trial status mix

COMPLETED11

ACTIVE_NOT_RECRUITING1

TERMINATED1

Phase mix

PHASE26

PHASE32

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.